Table 1.

Summary of Cases Treated with MMF for CIP

No.	Disease	ICIs	CIP Status	MMF Dosage	Combined Immune Modulators	CIP Outcome
121	ES-SCLC	Sintilimab	Grade 2 relapsed to Grade 3 with fungal and bacterial infections	1.5g bid	Methylprednisolone, Infliximab	Poorly controlled CIP, death, survival 76 days
221	LUSC Stage IV	Sintilimab	Grade 3 relapse with fungal and bacterial infections	1g bid	Methylprednisolone, IVIG (not used during relapse)	Initial response, poorly controlled CIP after relapse, death, survival 58 days
322	LUSC Stage IVB	Pembrolizumab	Grade 2 steroid-resistant, relapsed to Grade 3	1g qd	Prednisolone	Complete remission, no recurrence of CIP or lung cancer
422	LUSC Stage IVA	Pembrolizumab	Grade 3 steroid-resistant, relapse	1g qd	Prednisolone	Complete remission, no CIP recurrence, but lung cancer progressed
523	LS-SCLC	Atezolizumab	Grade 3 with radiation-related pneumonia and bacterial infection	1g bid	Methylprednisolone, Infliximab, IVIG	Significant symptom relief, radiological improvement, but liver metastasis progressed
624	LUSC Stage IIB	Atezolizumab	Grade 4 with Klebsiella pneumoniae infection	1g bid	Methylprednisolone, IVIG	Significant symptom relief, radiological improvement
725	LUSC	Pembrolizumab	Grade 4 with cytomegalovirus infection	NA	Prednisone, IVIG	Disease worsened, death
826	Melanoma Stage IV	Pembrolizumab	Pneumonia relapse after steroid tapering	Bid	Prednisone, Infliximab	Steroid and MMF-resistant, rapid and durable response to infliximab, melanoma-maintained remission

Abbreviations: ES-SCLC, Extensive-Stage Small Cell Lung Cancer; LUSC, Lung Squamous Cell Carcinoma; LS-SCLC, Limited-Stage Small Cell Lung Cancer; NA, Not Available.